UGT2B17 and B-cell chronic lymphocytic leukemia: This first set of data supports an interplay between UGT2B17 and the BCR signalosome at the transcriptional, translational, and posttranslational levels both in CLL patients’ cells and leukemic cell models and implies that UGT2B17 might prime the BCR pathway leading to the increased BCR signaling known to increase proliferation and survival of B-cells and more active disease.